Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin S Rhee

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|March 26, 2026
Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 WeeksLaurie A VanderVeen, Lisa Selzer, Silvia Chang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 20, 2013
The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatmentRobert Douglas Bruce, Peter Winkle, Joseph M Custodio, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adultsPeter J Ruane, Edwin DeJesus, Daniel Berger, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
AIDS (London, England)|February 6, 2025
Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administeredOnyema E Ogbuagu, Anchalee Avihingsanon, Sorana Segal-Maurer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2014
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairmentFrank A Post, Jonathan Winston, Jaime F Andrade-Villanueva, et al.
HIV Clinical Trials|December 1, 2014
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairmentCheryl K McDonald, Claudia Martorell, Moti Ramgopal, et al.
The Pediatric Infectious Disease Journal|March 12, 2015
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppressionXavier Saez-Llorens, Elizabeth Castaño, Mobeen Rathore, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsAndrew Zolopa, Paul E Sax, Edwin DeJesus, et al.
The Journal of Infectious Diseases|January 28, 2025
Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsNicolas A Margot, Vamshi Jogiraju, Nina Pennetzdorfer, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Acquired Immune Deficiency Syndromes (1999)|March 26, 2026
Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 WeeksLaurie A VanderVeen, Lisa Selzer, Silvia Chang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 20, 2013
The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatmentRobert Douglas Bruce, Peter Winkle, Joseph M Custodio, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adultsPeter J Ruane, Edwin DeJesus, Daniel Berger, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
AIDS (London, England)|February 6, 2025
Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administeredOnyema E Ogbuagu, Anchalee Avihingsanon, Sorana Segal-Maurer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2014
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairmentFrank A Post, Jonathan Winston, Jaime F Andrade-Villanueva, et al.
HIV Clinical Trials|December 1, 2014
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairmentCheryl K McDonald, Claudia Martorell, Moti Ramgopal, et al.
The Pediatric Infectious Disease Journal|March 12, 2015
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppressionXavier Saez-Llorens, Elizabeth Castaño, Mobeen Rathore, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsAndrew Zolopa, Paul E Sax, Edwin DeJesus, et al.
The Journal of Infectious Diseases|January 28, 2025
Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsNicolas A Margot, Vamshi Jogiraju, Nina Pennetzdorfer, et al.
Pageof 4